Peter Olupot-Olupot/Am J Hematol

Reducing transfusion utilization for children with sickle cell anemia in sub-Saharan Africa with hydroxyurea: Analysis from the phase I/II REACH trial.Power-Hays A Tomlinson GA Tshilolo L Santos B Williams TN Olupot-Olupot P Smart LR Aygun B Lane A Stuber SE Latham T Ware RE
Am J Hematol, (2024). 99:625-632

A predictive algorithm for identifying children with sickle cell anemia among children admitted to hospital with severe anemia in Africa.Olupot-Olupot P Connon R Kiguli S Opoka RO Alaroker F Uyoga S Nakuya M Okiror W Nteziyaremye J Ssenyondo T Nabawanuka E Kayaga J Williams Mukisa C Amorut D Muhindo R Frost G Walsh K Macharia AW Gibb DM Walker AS George EC Maitland K Williams TN
Am J Hematol, (2022). 97:527-536

Realizing effectiveness across continents with hydroxyurea: Enrollment and baseline characteristics of the multicenter REACH study in Sub-Saharan Africa.McGann PT Williams TN Olupot-Olupot P Tomlinson GA Lane A Luis Reis da Fonseca J Kitenge R Mochamah G Wabwire H Stuber S Howard TA McElhinney K Aygun B Latham T Santos B Tshilolo L Ware RE Reach Investigators
Am J Hematol, (2018). 93:537-545